Literature DB >> 30308088

Update on pharmacologically-relevant vitamin D analogues.

Glenville Jones1, Martin Kaufmann1.   

Abstract

Pharmacologists have been interested in vitamin D since its metabolism was elucidated in the early 1970s. Despite the synthesis of thousands of vitamin D analogues in the hope of separating its calcemic and anti-proliferative properties, few molecules have reached the market for use in the treatment of clinical conditions from psoriasis to chronic kidney disease. This review discusses vitamin D drugs, recently developed or still under development, for use in various diseases, but in particular bone disease. In the process we explore the mechanisms postulated to explain the action of these vitamin D analogues including action through the vitamin D receptor, action through other receptors e.g. FAM57B2 and dual action on transcriptional processes.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  bioequivalence; cytochrome P450; drug development; genetics and pharmacogenetics; pharmacokinetics; therapeutic drug monitoring

Mesh:

Substances:

Year:  2018        PMID: 30308088      PMCID: PMC6533488          DOI: 10.1111/bcp.13781

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  54 in total

1.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.

Authors:  Nirupama K Shevde; Lori A Plum; Margaret Clagett-Dame; Hironori Yamamoto; J Wesley Pike; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Aromatic-Based Design of Highly Active and Noncalcemic Vitamin D Receptor Agonists.

Authors:  Pranjal Gogoi; Samuel Seoane; Rita Sigüeiro; Thierry Guiberteau; Miguel A Maestro; Román Pérez-Fernández; Natacha Rochel; Antonio Mouriño
Journal:  J Med Chem       Date:  2018-05-22       Impact factor: 7.446

3.  ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects.

Authors:  Toshio Matsumoto; Noboru Kubodera
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12-23       Impact factor: 4.292

4.  (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.

Authors:  Seiichi Ishizuka; Noriyoshi Kurihara; Sakamuri V Reddy; Jillian Cornish; Tim Cundy; G David Roodman
Journal:  Endocrinology       Date:  2004-12-23       Impact factor: 4.736

5.  The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency.

Authors:  J C Gallagher; B L Riggs; R R Recker; D Goldgar
Journal:  Proc Soc Exp Biol Med       Date:  1989-07

Review 6.  Retiferols - synthesis and biological activity of a conceptually novel class of vitamin D analogs.

Authors:  Narasimha Rao Bolla; Ewa Marcinkowska; Geoffrey Brown; Andrzej Kutner
Journal:  Expert Opin Ther Pat       Date:  2014-03-22       Impact factor: 6.674

7.  Relation between 25-hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol.

Authors:  J Auwerx; R Bouillon; H Kesteloot
Journal:  Arterioscler Thromb       Date:  1992-06

8.  Extra-renal production of calcitriol in chronic renal failure.

Authors:  A Dusso; S Lopez-Hilker; N Rapp; E Slatopolsky
Journal:  Kidney Int       Date:  1988-09       Impact factor: 10.612

9.  Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women.

Authors:  J C Gallagher; C W Bishop; J C Knutson; R B Mazess; H F DeLuca
Journal:  J Bone Miner Res       Date:  1994-05       Impact factor: 6.741

10.  Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2.

Authors:  Corine Martineau; Roy Pascal Naja; Abdallah Husseini; Bachar Hamade; Martin Kaufmann; Omar Akhouayri; Alice Arabian; Glenville Jones; René St-Arnaud
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

View more
  5 in total

1.  Drugs for the treatment of metabolic bone diseases.

Authors:  Matthew T Drake; Serge Cremers; R Graham Russell; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2019-04-04       Impact factor: 4.335

Review 2.  Update on pharmacologically-relevant vitamin D analogues.

Authors:  Glenville Jones; Martin Kaufmann
Journal:  Br J Clin Pharmacol       Date:  2018-11-22       Impact factor: 4.335

3.  Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers.

Authors:  Milko Radicioni; Carol Caverzasio; Stefano Rovati; Andrea Maria Giori; Irma Cupone; Fabio Marra; Giuseppe Mautone
Journal:  Clin Drug Investig       Date:  2022-01-16       Impact factor: 2.859

4.  C3-Epimer of 25-Hydroxyvitamin D3 as a Superior Marker for Predicting the Severity of Chronic Kidney Disease in Rheumatoid Arthritis Patients.

Authors:  Jie Tang; Binwu Ying; Yuwei Yang; Bei Xu; Lin Yu; Wenqiang Jiang; Shutao Pu
Journal:  Oxid Med Cell Longev       Date:  2022-04-22       Impact factor: 7.310

5.  The 1α,25(OH)2D3 Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK Signaling.

Authors:  Jingjing Zhu; John P H Wilding
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-19       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.